Furthermore, since TNS4 modulates activated EGFR levels [88,89] and acts as a downstream effector in the Ras/Raf/Mek/MAPK cascade [83], combinatorial targeting of TNS4 and EGFR represents a theoretically viable strategy for EGFR-dysregulated cancers. The gene discussed is EGFR; the disease is cancer.